REVVITY INC
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Signature | Title | Date | |
| By: | /s/ PRAHLAD SINGH, PhD | President and Chief Executive Officer | February 27, 2024 |
|---|---|---|---|
| Prahlad Singh, PhD | (Principal Executive Officer) | ||
| By: | /s/ MAXWELL KRAKOWIAK | Sr. Vice President and Chief Financial Officer | February 27, 2024 |
| Maxwell Krakowiak | (Principal Financial Officer) | ||
| By: | /s/ ANITA GONZALES | Vice President and Controller | February 27, 2024 |
| Anita Gonzales | (Principal Accounting Officer) |
POWER OF ATTORNEY AND SIGNATURES
We, the undersigned officers and directors of Revvity, Inc., hereby severally constitute Prahlad Singh and Maxwell Krakowiak, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names, in the capacities indicated below, this Annual Report on Form 10-K and any and all amendments to said Annual Report on Form 10-K, and generally to do all such things in our name and behalf in our capacities as officers and directors to enable Revvity, Inc. to comply with the provisions of the Securities Exchange Act of 1934, and all requirements of the Securities and Exchange Commission, hereby rectifying and confirming signed by our said attorneys, and any and all amendments thereto.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:
| Signature | Title | Date | |
| By: | /s/ PRAHLAD SINGH, PhD | President, Chief Executive Officer and | February 27, 2024 |
|---|---|---|---|
| Prahlad Singh, PhD | Director (Principal Executive Officer) | ||
| By: | /s/ MAXWELL KRAKOWIAK | Sr. Vice President and | February 27, 2024 |
| Maxwell Krakowiak | Chief Financial Officer (Principal Financial Officer) | ||
| By: | /s/ ANITA GONZALES | Vice President and Controller | February 27, 2024 |
| Anita Gonzales | (Principal Accounting Officer) | ||
| By: | /s/ PETER BARRETT, PhD | Director | February 27, 2024 |
| Peter Barrett, PhD | |||
| By: | /s/ SAMUEL R. CHAPIN | Director | February 27, 2024 |
| Samuel R. Chapin | |||
| By: | /s/ SYLVIE GRÉGOIRE, PharmD | Director | February 27, 2024 |
| Sylvie Grégoire, PharmD | |||
| By: | /s/ MICHAEL A. KLOBUCHAR | Director | February 27, 2024 |
| Michael A. Klobuchar | |||
| By: | /s/ MICHELLE MCMURRY-HEATH, MD PhD | Director | February 27, 2024 |
| Michelle McMurry-Heath, MD PhD | |||
| By: | /s/ ALEXIS P. MICHAS | Director | February 27, 2024 |
| Alexis P. Michas | |||
| By: | /s SOPHIE V. VANDEBROEK, PhD | Director | February 27, 2024 |
| Sophie V. Vandebroek, PhD | |||
| By: | /s/ MICHEL VOUNATSOS | Director | February 27, 2024 |
| Michel Vounatsos | |||
| By: | /s/ FRANK WITNEY, PhD | Director | February 27, 2024 |
| Frank Witney, PhD | |||
| By: | /s/ PASCALE WITZ | Director | February 27, 2024 |
| Pascale Witz | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.